UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 12, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Semaglutide
2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the
programme
Bagsværd, Denmark, 12 June 2020 –
Novo Nordisk today announced headline results from the final two phase 3a clinical trials investigating once-weekly subcutaneous
(sc) semaglutide 2.4 mg for weight management. STEP 2 in adults with obesity and type 2 diabetes (T2D) and STEP 3 as an adjunct
to intensive behavioural therapy (IBT) in adults with obesity.
STEP 2 (obesity
and type 2 diabetes)
STEP 2 is a 68-week randomised, double-blind,
multicentre, placebo-controlled trial. The trial compared the efficacy and safety of once-weekly sc semaglutide 2.4 mg after 68
weeks to placebo and once-weekly sc semaglutide 1.0 mg. Treatment was provided in conjunction with lifestyle intervention, in 1,210
adults with T2D and either obesity or overweight with comorbidities.
The trial met
both primary endpoints. In all people randomised1, a statistically significant
greater weight loss of 9.6% was achieved at 68 weeks with sc semaglutide 2.4 mg, from a mean baseline bodyweight of 99.8 kg, compared
to placebo (3.4% weight loss) and sc semaglutide 1.0 mg (7.0% weight loss). 68.8% of those who received sc semaglutide 2.4 mg
achieved a weight loss of 5% or more after 68 weeks, compared to 28.5% with placebo.
When evaluating
the effects of treatment if taken as intended2, people treated with sc semaglutide
2.4 mg achieved a weight loss of 10.6%, compared to a 3.1% weight loss with placebo and 7.5% weight loss with semaglutide 1.0
mg at 68 weeks. 73.2% of those who stayed on sc semaglutide 2.4 mg for 68 weeks achieved a weight loss of 5% or more, compared
to 27.6% with placebo.
________________________
1
Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence
or initiation of other anti-obesity therapies
2
Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment
and did not initiate other anti-obesity therapies
Page 2 of 3
STEP 3 (adjunct to
intensive behavioural therapy)
STEP 3 is a 68-week randomised, double-blind,
multicentre, placebo-controlled trial. The trial investigated the effect of once-weekly sc semaglutide 2.4 mg after 68 weeks compared
to placebo in 611 adults with obesity or overweight with comorbidities. Both treatments were in conjunction with IBT, defined as
weekly behavioural support, dietician counselling and reduced calorie diet.
The trial met both of
its primary endpoints. In all people randomised1, a statistically significantly
greater weight loss of 16.0% was achieved with sc semaglutide 2.4 mg as an adjunct to IBT, from a mean baseline bodyweight of
105.8 kg, compared to a 5.7% weight loss with placebo plus IBT after the 68-week treatment period. 86.6% of those treated with
sc semaglutide 2.4 mg achieved a weight loss of 5% or more after 68 weeks as an adjunct to IBT, compared to 47.6% with placebo
plus IBT.
When evaluating the
effects of treatment if taken as intended2, people treated with sc semaglutide
2.4 mg plus IBT achieved a weight loss of 17.6%, compared to a 5.0% weight loss with placebo plus IBT. 89.8% of those who received
sc semaglutide 2.4 mg plus IBT achieved a weight loss of 5% or more after 68 weeks, compared to 50.0% with placebo plus IBT.
In both STEP 2 and
STEP 3, sc semaglutide 2.4 mg appeared to have a safe and well-tolerated profile, consistent with previous findings. The most
common adverse events among people treated with sc semaglutide 2.4 mg were gastrointestinal events. Most events were
transient, and mild or moderate in severity.
“These results continue to build on the
highly impressive weight loss reported previously in STEP 1 and 4. Altogether, the results indicate that semaglutide 2.4 mg will
play a key role in improving the treatment of people with obesity,” said Mads Krogsgaard Thomsen, executive vice president
and chief science officer of Novo Nordisk. “We have now reported on all the four trials in the STEP programme and we look
forward to sharing the results with regulatory authorities.”
About obesity and
sc semaglutide 2.4 mg for weight management
Obesity is a chronic disease that requires
long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications
are numerous and include T2D, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease
and cancer.
Once-weekly sc semaglutide 2.4 mg is being
investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon-like peptide-1
(GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less
and reduce their calorie intake.
Page
3 of 3
About the STEP clinical
programme
STEP (Semaglutide Treatment Effect in People
with obesity) is a phase 3 clinical development programme with once-weekly sc semaglutide 2.4 mg in obesity. The global clinical
phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.
STEP 1 – a 68-week safety and efficacy
trial of sc semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. The results were reported on 4 June.
STEP 2 – a 68-week safety and efficacy
trial of sc semaglutide 2.4 mg versus placebo and once-weekly sc semaglutide 1.0 mg once-weekly in 1,210 adults with type 2 diabetes
and either obesity or overweight.
STEP 3 – a 68-week safety and efficacy
trial of sc semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or
overweight.
STEP 4 – a 68-week
safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the
target dose of 2.4 mg after a 20-week run-in. The results were reported on 13 May.
About Novo Nordisk
Novo
Nordisk is a leading global healthcare company, founded in 1923
and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and
working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 38 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: June 12, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2023 to Mar 2024